ID.1
Item
treatment demanding multiple myeloma
boolean
C0026764 (UMLS CUI [1])
ID.2
Item
refractoriness to melphalan
boolean
C0025241 (UMLS CUI [1,1])
C0205269 (UMLS CUI [1,2])
ID.3
Item
acceptance of rules for prevention of pregnancy
boolean
C0009862 (UMLS CUI [1])
ID.4
Item
previous treatment with bortezomib, thalidomide, or lenalidomide
boolean
C1176309 (UMLS CUI [1,1])
C0039736 (UMLS CUI [1,2])
C1144149 (UMLS CUI [1,3])
ID.5
Item
sensory neuropathy grade iii or neuropathic pain grade ii
boolean
C0151313 (UMLS CUI [1,1])
C0003892 (UMLS CUI [1,2])
ID.6
Item
severe concomitant disorder, e.g. other malignancy or severe heart disease
boolean
C0012634 (UMLS CUI [1])
ID.7
Item
transformation to plasma cell leukemia or aggressive lymphoma
boolean
C0023484 (UMLS CUI [1,1])
C0024299 (UMLS CUI [1,2])
C0580822 (UMLS CUI [1,3])
ID.8
Item
frequent visits for bortezomib injections not feasible
boolean
C4276228 (UMLS CUI [1])
ID.9
Item
anticipated non-adherence to study protocol
boolean
C1321605 (UMLS CUI [1])
ID.10
Item
pregnancy
boolean
C0032961 (UMLS CUI [1])
ID.11
Item
anticipated non-adherence to rules for prevention of pregnancy
boolean
C1321605 (UMLS CUI [1,1])
C0032961 (UMLS CUI [1,2])
ID.12
Item
severe thrombocytopenia (thrombocyte count less than 25000/microliter)
boolean
C0040034 (UMLS CUI [1])